Autoantibody-mediated channelopathies at the neuromuscular junction

Neuroscientist

Volumn 3, Issue 5, 1997, Pages 337-346

  Newsom Davis, John ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Acetylcholine receptor; Calcium channel; Myasthenia; Neuromyotonia; Potassium channel

Indexed keywords

EID: 0002078145     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849700300515     Document Type: Article

References (59)

1. Lindstrom J, Shelton D, Fujii Y. Myasthenia gravis. Adv Immunol 1988;42:233-284.
2. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray NMF. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981;ii:224-226.
3. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 1991;338:75-77.
4. Elmqvist D, Hofmann WW, Kugelberg J, Quastel DMJ. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol (Lond) 1964;174:417-434.
5. Lindstrom JM, Lambert EH. Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton-Lambert syndrome. Neurology 1978;28:130-138.
6. Newsom-Davis J, Vincent A, Willcox N. Autoimmune disorders of the neuromuscular junction. In: Lachmann PJ, Peters DK, Rosen FS, Walport MJ, editors. Clinical aspects of immunology. 5th ed. Oxford: Blackwell Scientific Publications; 1993. p. 2091-2111.
7. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-1252.
8. Yamamoto T, Vincent A, Ciulla TA, Lang B, Johnston I, Newsom-Davis J. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann Neurol 1991;30:550-557.
9. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1986;i:116-119.
10. Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994;17:1393-1400.
11. Barrett-Jolley R, Byrne N, Vincent A, Newsom-Davis J. Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in TE671/RD muscle cell line. Pflugers Arch 1994;428: 492-498.
12. Li Z, Forester N, Vincent A. Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. J Neuroimmunol 1996;64:179-183.
13. Glennerster A, Palace J, Warburton D, Oxbury S, Newsom-Davis J. Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment. Neurology 1996;46:1138-1142.
14. Karlin A. Structure of nicotinic acetylcholine receptors. Curr Opin Neurobiol 1993;3:299-309.
15. Beeson D, Jeremiah S, West LF, Povey S, Newsom-Davis J. Assignment of the human nicotinic acetylcholine receptor genes: the α- and δ-subunit genes to chromosome 2 and the β-subunit gene to chromosome 17. Ann Hum Genet 1990;54:199-208.
16. Beeson D, Morris A, Vincent A, Newsom-Davis J. The human muscle nicotinic acetylcholine receptor α-subunit exists as two isoforms: a novel exon. EMBO J 1990;9:2101-2106.
17. Mamalaki A, Tzartos SJ. Nicotinic acetylcholine receptor: structure, function and main immunogenic region. Adv Neuroimmunol 1994;4:339-354.
18. Vincent A, Newland C, Brueton L, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24-25.
19. Riemersma S, Vincent A, Beeson D, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996;98: 2358-2363.
20. Kaminski HJ, Maas E, Spiegel P, Ruff RL. Why are eye muscles frequently involved in myasthenia gravis. Neurology 1990;40: 1663-1669.
21. Newsom-Davis J. Myasthenia gravis and the Miller-Fisher variant of Guillain-Barré syndrome. Curr Opin Neurol 1997;10:18-21.
22. MacLennan C, Beeson D, Buijs A-M, Vincent A, Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 1997; 41:423-431.
23. Hawke S, Matsuo H, Nicolle M, Malcherek G, Melms A, Willcox N. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol Today 1996;17: 307-311.
24. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994;93: 1361-1369.
25. Mygland A, Kuwajima G, Mikoshiba K, Tysnes O-B, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995;62:79-83.
26. MacLennan C, Beeson D, Willcox N, Vincent A, Newsom-Davis J. Expression of messenger RNA encoding muscle acetylcholine receptor ε-subunit in thymoma. Ann Neurol 1996;40:513.
27. Anderson HJ, Churchill-Davidson HC, Richardson AT. Bronchial neoplasm with myasthenia. Lancet 1953;ii:1291-1293.
28. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasma. Am J Physiol 1956; 187:612-613.
29. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-596.
30. Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci 1971; 183:183-199.
31. Molenaar PC, Newsom-Davis J, Polak RL, Vincent A. Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle. Neurology 1982;32:1062-1065.
32. Fukunaga H, Engel AG, Osame M, Lambert EH. Paucity and dis-organisation of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5:686-697.
33. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 1983;80:7636-7640.
34. Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol (Lond) 1983;344: 335-345.
35. Lang B, Newsom-Davis J, Peers C, Prior C, Wray DW. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol (Lond) 1987;390:257-270.
36. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87.
37. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
38. Nagel A, Engel AG, Lang B, Newsom-Davis J, Fukuoka T. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann Neurol 1988;24:552-558.
39. Engel AG, Nagel A, Fukuoka T, et al. Motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Morphologic evidence for depletion and that the depletion is mediated by autoantibodies. Ann N Y Acad Sci 1989;560:278-290.
40. 2+ channels in mammalian central neurons. Trends Neurosci 1995;18:89-98.
41. Katz E, Ferro PA, Weisz G, Uchitel OD. Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction. J Physiol (Lond) 1996;497.3: 687-697.
42. Rosenfeld MR, Wong E, Dalmau J, et al. Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen. Ann Neurol 1993;33:113-120.
43. Waterman SA, Lang B, Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol. In press 1997.
44. 2+ flux in a human small cell carcinoma line. Nature 1985;317:737-739.
45. Kim YI, Neher E. IgG from patients with Lambert-Eaton syndrome blocks voltage dependent calcium channels. Science 1988;239:405-408.
46. De Aizpurua, Lambert EH, Griesmann GE, Olivera BO, Lennon VA. Antagonism of voltage-gated calcium channels in small cell carcinomas of patients with and without Lambert-Eaton myasthenic syndrome by autoantibodies, to-conotoxin and adenosine. Cancer Res 1988;48:4719-4724.
47. Peers C, Lang B, Newsom-Davis J, Wray DW. Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma X glioma cell line. J Physiol (Lond) 1990; 421:293-308.
48. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40: 1552-1556.
49. Morris CS, Esiri MM, Marx A, Newsom-Davis J. Immunocytochemical characteristics of small cell lung carcinoma associated with the Lambert-Eaton myasthenic syndrome. Am J Pathol 1992; 140:839-845.
50. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome): report of 5 cases and literature review. Brain 1993;116:453-469.
51. Isaacs H. A syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry 1961;24:319-325.
52. + channels of peripheral nerves. Ann Neurol 1995;38:714-722.
53. Pongs O. Molecular biology of voltage-dependent potassium channels. Physiol Rev 1992;72:S69-S88.
54. + channel genes. In: North RA, editor. Handbook of receptors and channels. Boca Raton (FL): CRC Press; 1995. p. 1-71.
55. Watson S, Abbott A. Receptor and ion channel nomenclature supplement 1996. 7th ed. Trends Pharmacol Sci 1996;17(Suppl):69S-78S.
56. + channels are implicated in neuromyotonia. Ann Neurol 1997;41:238-246.
57. Newsom-Davis J. Autoimmune neuromyotonia (Isaacs' syndrome): an antibody-mediated potassium channelopathy. Ann NY Acad Sci. In press 1997.
58. + channel blocking factor in the cerebrospinal fluid. Pflugers Arch 1992;421: 552-557.
59. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994;265:648-651.